Supercritical fluid micronization of risperidone pharmaceutical substance

Abstract

A comparative study of the supercritical fluid micronization of risperidone pharmaceutical substance with an initial particle size of 50 to 100 μm by the RESS and SAS methods aimed at increasing the bioavailability of risperidone as a drug was performed. Both methods makes it possible to prepare risperidone particle of various forms, 5–20 μm in size. However, the SAS method is preferable, because in contrast to RESS, it does not cause contamination of risperidone with organic solvents used in both processes or any other impurities and also makes it possible to vary the shape and size of particles. It is shown that, during SAS micronization, the polymorphic form of risperidone changes from triclinic to monoclinic.